IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 35.341
AS - Asia 3.361
NA - Nord America 1.417
SA - Sud America 298
AF - Africa 71
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 40.493
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 34.737
SG - Singapore 1.501
US - Stati Uniti d'America 1.349
CN - Cina 895
VN - Vietnam 595
FR - Francia 289
BR - Brasile 192
FI - Finlandia 109
HK - Hong Kong 105
DE - Germania 56
AR - Argentina 51
MX - Messico 43
GB - Regno Unito 41
JP - Giappone 38
IQ - Iraq 32
BD - Bangladesh 31
ID - Indonesia 23
IN - India 22
ZA - Sudafrica 19
EC - Ecuador 18
PH - Filippine 17
CH - Svizzera 14
IE - Irlanda 14
VE - Venezuela 13
CA - Canada 12
NL - Olanda 12
TH - Thailandia 12
TR - Turchia 12
RU - Federazione Russa 11
SA - Arabia Saudita 11
DZ - Algeria 10
CL - Cile 9
CO - Colombia 9
ES - Italia 9
PK - Pakistan 9
NP - Nepal 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
KE - Kenya 7
MA - Marocco 7
TW - Taiwan 7
TN - Tunisia 6
UA - Ucraina 6
LB - Libano 5
PL - Polonia 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
MY - Malesia 4
RO - Romania 4
SE - Svezia 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
MU - Mauritius 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CR - Costa Rica 2
EG - Egitto 2
ET - Etiopia 2
HR - Croazia 2
LT - Lituania 2
MM - Myanmar 2
OM - Oman 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BZ - Belize 1
CD - Congo 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
KR - Corea 1
KW - Kuwait 1
MK - Macedonia 1
ML - Mali 1
MQ - Martinica 1
NE - Niger 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SI - Slovenia 1
Totale 40.489
Salva come PNG Salva come JPEG
Città #
Genova 21.519
Genoa 8.327
Rapallo 2.417
Vado Ligure 2.268
Singapore 685
San Jose 604
Lauterbourg 272
Ho Chi Minh City 168
Hanoi 139
Ashburn 116
Beijing 109
Council Bluffs 108
Hong Kong 103
Helsinki 95
New York 79
Santa Clara 61
Frankfurt am Main 45
Bordighera 39
Tokyo 36
Haiphong 32
Los Angeles 25
Da Nang 24
Mexico City 24
Milan 22
Orem 21
São Paulo 21
Tianjin 18
Rome 15
Chicago 14
Zurich 14
Lappeenranta 13
Cardiff 12
Dublin 12
Turin 12
Guangzhou 11
Can Tho 10
Baghdad 9
Biên Hòa 9
Hải Dương 9
London 9
Atlanta 8
Agawam 7
Amman 7
Amsterdam 7
Buenos Aires 7
City of London 7
Des Moines 7
Guayaquil 7
Johannesburg 7
Nairobi 7
Quận Ba 7
Shanghai 7
Thái Bình 7
Dallas 6
Jeddah 6
Montreal 6
Ninh Bình 6
Nuremberg 6
Bologna 5
Buffalo 5
Bắc Ninh 5
Cape Town 5
Dhaka 5
Erbil 5
Quito 5
Reggio Emilia 5
Warsaw 5
Bangkok 4
Brescia 4
Chennai 4
Curitiba 4
Hangzhou 4
Huntington 4
Karbala 4
Orangeburg 4
Phủ Lý 4
Shenzhen 4
Sumaré 4
Thái Nguyên 4
Vĩnh Long 4
Abidjan 3
Ankara 3
Bogotá 3
Brest 3
Bến Tre 3
Caracas 3
Charlotte 3
Florence 3
Hortolândia 3
Imus 3
Istanbul 3
Joinville 3
Lima 3
Madrid 3
Manchester 3
Marseille 3
Miami 3
Milwaukee 3
Modena 3
Newark 3
Totale 37.805
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 313
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 232
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 222
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care 221
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 218
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 217
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 214
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 213
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 209
Acromegaly is associated with increased cancer risk: A survey in Italy 209
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 208
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 208
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 205
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 201
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 200
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 200
Pituitary image: pituicytoma. 198
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 197
Computed tomography colonography in acromegaly 194
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 189
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 188
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 187
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 186
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 185
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 183
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 183
"Present and future of immunotherapy in Neuroendocrine Tumors" 183
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 182
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 180
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 178
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 178
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 178
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 177
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 177
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 177
The pathology of the ulnar nerve in acromegaly. 175
Hormone receptors analysis in idiopathic progressive subglottic stenosis 175
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 175
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 175
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 174
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system 173
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 173
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 172
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 171
A pilot study on nerve ultrasound in acromegaly 168
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 168
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 167
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 166
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 166
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 164
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 163
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 162
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 160
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 159
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 159
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 159
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 158
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 158
On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic 157
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 157
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 157
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 156
Initial staging of lymphoma with octreotide and other receptor imaging agents. 156
Somatostatin receptor scintigraphy in thoracic diseases 155
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 155
Doe4s biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors? 155
Managing Cushing's disease: The state of the art 155
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 154
Rare diseases in clinical endocrinology: A taxonomic classification system 154
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 153
Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients 153
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 152
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 152
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 152
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 152
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 151
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 151
Somatostatin receptor ligands in the treatment of acromegaly 151
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 151
A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency 151
Dopamine receptor expression and function in corticotroph ectopic tumors. 150
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 150
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 149
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 149
Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. 148
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 148
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 147
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 147
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 146
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 145
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. 144
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors 144
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 144
Trigger Finger, an Early Musculoskeletal Manifestation of Acromegaly 143
Sympathovagal imbalance in acromegalic patients 142
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 142
OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells 142
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database 142
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. 142
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 142
Totale 17.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.757
article - articoli 128.568
book - libri 0
conference - conferenze 638
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 551
Totale 259.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021642 0 0 0 0 0 0 0 0 0 284 190 168
2021/20223.426 98 221 283 437 90 251 257 736 174 317 163 399
2022/20232.958 329 208 39 270 442 524 23 219 531 26 302 45
2023/20241.652 90 221 39 186 131 283 108 69 100 66 100 259
2024/20255.496 153 423 155 368 781 573 564 784 247 267 502 679
2025/20269.052 1.078 332 1.010 921 1.120 1.032 1.611 419 774 755 0 0
Totale 41.106